Completed PHASE1 INTERVENTIONAL 2-arm NCT01506661

Safety of Zostavax Vaccination in Rheumatoid Arthritis

Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis

Sponsor: Oklahoma Medical Research Foundation

Conditions Rheumatoid Arthritis Varicella Zoster

Interventions Zostavax (varicella zoster virus) vaccine

Updated 7 times since 2017 Last updated: Mar 4, 2020 Started: Jan 31, 2012 Primary completion: Dec 31, 2017 Completion: Oct 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Rheumatoid Arthritis and Varicella Zoster, this trial is completed. The trial is conducted by Oklahoma Medical Research Foundation and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Oct 2019 — Apr 2020 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Oct 2019 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oklahoma Medical Research Foundation

Data source: Oklahoma Medical Research Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oklahoma City, United States